Sui 細胞株に関する遺伝的性質について

細胞樹立者・寄託者が Sui 細胞株に関する遺伝的性質を「Yanagihara K., Iino Y., Yokozaki H., et al.　A Comparative Study of Patient-Derived Tumor Models of Pancreatic Ductal Adenocarcinoma Involving Orthotopic Implantation. Pathobiology (DOI:10.1159/000521714)」に発表しています。重要な情報ですのでご確認ください。

About the genetic properties of Sui cell lines

Cell establishers and depositors have published the genetic properties of Sui cell lines in Pathobiology (DOI: 10.1159 / 000521714). Please check it as it is important information.

Comparing Genetic Alterations of PDX, PDCL, and CDX[a]

Strain	Gene	CDS Change	AA Change	Variant Ratio		
				PDX	PDCL	CDX
65	CDKN2A	441_441delC	A148fs*9	84.8	94.8	97.9
	KRAS	G35A	G12D	56.5	57.4	61.5
	TP53	G743A	R248Q	90.2	99.9	99.9
	SMAD4	Homozygous deletion		Yes	Yes	Yes
66	CDKN2A	299_303delCCGGG	A100fs*18	87.4	88.8	88.6
	KRAS	G35A	G12D	51.8	50.5	49.7
	AKT2	Amplification		Yes (4.1X)	Yes (4.1X)	Yes (3.8X)
67	KRAS	G35A	G12D	63.0	65.9	68.6
	TP53	C742T	R248W	100.0	99.8	99.8
	SMAD4	Homozygous deletion		Yes	Yes	Yes
68	KRAS	G35A	G12D	99.8	100.0	99.9
	TP53	G733A	G245S	100.0	100.0	100.0
	CDKN2A	Homozygous deletion		Yes	Yes	Yes
69	KRAS	G35T	G12V	66.8	65.3	65.2
	TP53	G524A	R175H	100.0	100.0	99.9
	CDKN2A	Homozygous deletion		Yes	Yes	Yes
70	KRAS	G35T	G12V	78.5	78.6	81.4
	TP53	G524A	R175H	99.6	99.9	100.0
	CDKN2A	132_132delC	Y44fs*9	95.4	95.1	94.8
	SMAD4	Homozygous deletion		Yes	Yes	Yes
71	KRAS	G35A	G12D	99.8	99.8	NA
	SMAD4	Homozygous deletion		Yes	Yes	NA
72	PIK3CA	G1633A	E545K	49.4	50.3	50.3
	TP53	G404A	C135Y	99.8	100.0	99.9
73	KRAS	A183C	Q61H	45.3	50.2	38.5
	CTNNB1	G101A	G34E	48.4	46.8	47.7
	MLH1	1484_1484delC	R497fs*11	12.5	ND	ND
	MLH1	906_906delT	N302fs*65	45.7	45.9	46.6
	ARIDA1A	2760_2761insG	M923fs*13	42.8	45.4	41.8
	ARIDA1A	5542_5542delG	D1850fs*33	46.6	40.3	43.5
	ALK	833_834insA	P279fs*4	43.0	42.6	41.6
	NOTCH2	4063_4063delG	E1355fs*72	43.7	45.5	43.0
	ROS1	3543_3546delAAGA	R1182fs*60	40.4	41.3	38.1
	SMAD4	89_90delGA	S32*	42.2	42.1	45.5
	SMARCA4	805_805delC	M272fs*31	50.2	46.4	43.3
	SMARCA4	3436_3436delG	G1146fs*18	51.8	49.1	49.3

	ARAF	18_18delC	P8fs*26	46.4	ND	ND
	PTCH1	3921_3921delC	R1308fs*64	ND	ND	24.0
74	KRAS	G34C	G12R	57.0	52.7	72.6
	KDM6A	702_703delAG	N236fs*26	90.0	92.8	91.4
	SMAD4	1582_1583delCA	H528fs*25	93.1	95.5	95.1
	RB1	Homozygous deletion		Yes	Yes	Yes
75	KRAS	G35A	G12D	100.0	99.9	99.9
	TP53	691_692delAC	T231fs*8	94.0	95.6	93.4
	SMARCA4	4830_4833delGGGC (exon 34)	G1611fs*15	85.5	81.0	83.0
	CDKN2A	Homozygous deletion		Yes	Yes	Yes
	SMARCA4	Homozygous deletion (exons 1-33)		Yes	Yes	Yes
76	KRAS	G35A	G12D	99.9	99.9	99.8
	TP53	691_692delAC	T231fs*8	94.2	95.2	97.4
	SMARCA4	4830_4833delGGGC (exon 34)	G1611fs*15	83.9	79.8	81.4
	CDKN2A	Homozygous deletion		Yes	Yes	Yes
	SMARCA4	Homozygous deletion (exons 1-33)		Yes	Yes	Yes
77	KRAS	G38A	G13D	99.8	99.9	99.7
	TP53	441_441delT	D148fs*22	95.5	96.2	96.4
	CCND1	Amplification		Yes (9.6X)	Yes (7.3X)	Yes (10.0X)

[a] Genomic DNA from the PDX and CDX tumors and PDCLs was prepared using a QIAamp DNA Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol. NGS analyses were performed using the NCC oncopanel (v4) for 114 cancer-related genes. Targeted sequencing and data analysis have been described previously. CDS; coding sequence, AA; amino acid, NA; not available, ND; not detected.